ArticleThe Malaysian journal of medical sciences : MJMS2025
The Potential of Trigona Honey as a Supplementary Therapy for Vascular Cognitive Impairment in Patients with Acute Ischaemic Stroke.
Article in The Malaysian journal of medical sciences : MJMS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vascular cognitive impairment (VCI) is a common, yet often underrecognised, consequence of acute ischaemic stroke. Despite its prevalence, therapeutic strategies targeting VCI remain limited. Trigona honey, known for its antioxidant and neuroprotective properties, may offer a novel adjunctive intervention to improve cognitive outcomes after stroke. Methods: This randomised controlled study involved 48 patients diagnosed with acute ischaemic stroke. Participants were randomly assigned to two equal groups: an intervention group receiving daily supplementation with Trigona honey ( Results: At baseline, 66.7% of participants were male, with most exhibiting mild cognitive impairment. After three months, the intervention group showed significant improvement in MOCA scores (from 20.08 ± 4.53 to 24.33 ± 3.64), while the control group showed only a modest increase (from 18.42 ± 5.12 to 19.67 ± 6.31). The between-group difference in MOCA scores was 4.25 (95% CI: 3.07, 5.43; Conclusion: Trigona honey supplementation significantly improved cognitive performance and functional outcomes in patients with VCI following ischaemic stroke, supporting its role as a promising adjunct in stroke rehabilitation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.